Physician profile
Ram Trehan
NPI 1952310070
$26,386.85
in general payments reported to CMS, 2019-2025
67 companies · $2,271 in 2025
The $2,271 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $924 · 2020: $437 · 2021: $2,000 · 2022: $12K · 2023: $4,524 · 2024: $4,591 · 2025: $2,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,648 · Consulting Fee: $3,044 · Honoraria: $1,500 · Travel and Lodging: $1,080 · Long Term Medical Supply Or Device Loan: $997 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,647.55 |
| Consulting Fee | $3,044.00 |
| Honoraria | $1,500.00 |
| Travel and Lodging | $1,080.16 |
| Long Term Medical Supply Or Device Loan | $997.00 |
| Education | $117.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Labcorp Holdings INC. | $3,890.44 | 2022 | |
| Exelixis INC. | $3,730.12 | 2022-2025 | Cabometyx |
| Pharmacosmos Therapeutics INC. | $2,641.86 | 2022-2025 | Monoferric |
| Genzyme Corporation | $2,196.62 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $2,051.28 | 2019-2025 | Opdivo, Augtyro, Eliquis |
| Novartis Pharmaceuticals Corporation | $1,685.38 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $1,433.24 | 2019-2023 | Rezlidhia, Tavalisse |
| Janssen Biotech, INC. | $1,365.68 | 2019-2025 | Darzalex, Erleada, Tecvayli |
| Veracyte, INC. | $993.96 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $450.56 | 2019-2025 | Alunbrig, Ninlaro, Iclusig |
| Abbvie INC. | $439.27 | 2022-2025 | Qulipta, Ubrelvy, Venclexta |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $326.09 | 2019-2024 | Calquence, Imfinzi |
| Celgene Corporation | $313.80 | 2019-2025 | Reblozyl, Pomalyst |
| Pfizer INC. | $303.83 | 2019-2025 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $260.69 | 2019-2025 | |
| Daiichi Sankyo INC. | $248.58 | 2022-2024 | Injectafer, Enhertu |
| Amgen INC. | $207.36 | 2020-2024 | Prolia, Evenity, Lumakras |
| Seagen INC. | $173.06 | 2022-2023 | Tukysa, Tivdak, Padcev |
| Genentech USA, INC. | $168.36 | 2019-2024 | Lunsumio, Polivy, Columvi |
| Astellas Pharma US INC | $154.92 | 2023-2025 | Padcev |
| Pharmacyclics LLC, An Abbvie Company | $154.03 | 2019-2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $148.45 | 2019-2024 | Keytruda, Lynparza |
| Gilead Sciences, INC. | $147.95 | 2022-2025 | Trodelvy |
| Taiho Oncology, INC. | $135.66 | 2024-2025 | |
| Tersera Therapeutics LLC | $125.09 | 2022-2025 | Zoladex, Xermelo |
| Sobi, INC | $123.14 | 2022-2025 | |
| Novo Nordisk INC | $122.89 | 2021 | |
| Spectrum Pharmaceuticals INC. | $121.27 | 2023-2025 | Rolvedon |
| Asd Specialty Healthcare, LLC | $111.85 | 2019 | |
| Medtronic, INC. | $109.45 | 2021 | |
| Beone Medicines USA, INC. | $99.16 | 2025 | Brukinsa, Tevimbra |
| Morphosys, US INC. | $92.55 | 2022-2023 | Monjuvi |
| Eisai INC. | $91.82 | 2022-2025 | |
| Cti Biopharma Corp. | $89.20 | 2022 | |
| Lilly USA, LLC | $87.65 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Pharmaessentia USA Corporation | $84.46 | 2022-2025 | Besremi |
| Incyte Corporation | $81.54 | 2022-2025 | Jakafi |
| Cardinal Health 108 LLC | $77.86 | 2019 | |
| Alexion Pharmaceuticals, INC. | $73.12 | 2019-2024 | Ultomiris |
| Global Blood Therapeutics, INC. | $68.95 | 2022 | |
| Mirati Therapeutics, INC. | $66.47 | 2023-2024 | Krazati |
| Regeneron Healthcare Solutions, INC. | $65.53 | 2022-2025 | Libtayo |
| Array Biopharma INC | $59.01 | 2023-2025 | Braftovi, Mektovi, Xalkori |
| Amneal Pharmaceuticals LLC | $53.44 | 2024-2025 | Avastin, Alymsys |
| G1 Therapeutics, INC. | $48.88 | 2023 | Cosela |
| Novocure INC. | $46.95 | 2023-2024 | Optune Lua (Novottf-200t), Optune |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.96 | 2024-2025 | |
| Coherus Oncology, INC. | $44.33 | 2020-2025 | Loqtorzi |
| Glaxosmithkline, LLC. | $44.16 | 2023-2024 | Jemperli, Zejula |
| Aveo Pharmaceuticals, INC. | $38.23 | 2025 | |
| Mylan Institutional INC. | $28.32 | 2023 | Hulio |
| Deciphera Pharmaceuticals INC. | $27.43 | 2023 | Qinlock |
| Heron Therapeutics, INC. | $26.15 | 2022 | |
| Legend Biotech USA INC. | $25.73 | 2025 | Carvykti |
| Adc Therapeutics America, INC. | $24.66 | 2025 | |
| Octapharma USA, INC. | $24.65 | 2022 | |
| Myriad Genetic Laboratories, INC. | $21.54 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $20.96 | 2024 | Tazverik |
| Blueprint Medicines Corporation | $20.77 | 2022 | |
| Puma Biotechnology, INC. | $19.98 | 2020 | |
| Karyopharm Therapeutics INC. | $18.87 | 2022 | |
| Lundbeck LLC | $18.31 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $17.75 | 2019 | |
| Accord Healthcare, INC. | $17.32 | 2025 | |
| Janssen Pharmaceuticals, INC | $16.52 | 2019 | |
| Recordati_rare_diseases_inc. | $13.74 | 2023 | Sylvant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ram Trehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.